Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes

Fumiaki Tanaka, Hiroshi Yamaguchi, Naotsugu Haraguchi, Kohjiro Mashino, Mitsuhiko Ohta, Hiroshi Inoue, Masaki Mori

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Dendritic cells (DCs) are powerful antigenpresenting cells (APCs), that have so far been applied for cancer specific immunotherapy. Recent results suggest that matured DCs derived from human monocytes have a significant impact on the outcome of vaccination. The conventional generation of mature DCs from human monocytes in vitro has been reported to require 5 days for differentiation with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and 2 days for stimulation. We herein report a new strategy for the functional maturation of monocyte-derived DCs within only 2 days of in vitro culture and the induction of specific cytotoxic T lymphocytes (CTLs) to tumor rejection peptide. The monocytes were incubated for 1 day with GM-CSF and IL-4, followed by activation with a bacterial product, OK-432 and prostaglandin E 2 (PGE2) for another 1 day (rapid DC). Rapid DC expressed mature DC surface markers as well as chemokine receptor 7 and secreted Th1-type cytokines. The DCs genereated in this study mobilized Ca2+ in response to CCL21/6Ckine and SDF-1, but only marginally did so to Mip-1α. Moreover, when rapid DC were compared with mature conventional 7-day DCs, they were equally potent in inducing specific CTLs in vitro. These results indicate that the rapid DC is as effective as the monocyte-derived conventional DCs. The rapid DC would be a potentially useful new cancer-specific immunotherapy.

Original languageEnglish
Pages (from-to)1263-1268
Number of pages6
JournalInternational Journal of Oncology
Volume29
Issue number5
Publication statusPublished - Nov 1 2006

Fingerprint

Cytotoxic T-Lymphocytes
Dendritic Cells
Monocytes
Cultured Cells
Peptides
Neoplasms
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4
Immunotherapy
Chemokine CCL21
Picibanil
Chemokine Receptors
Cell Surface Receptors
Prostaglandins E
Interleukin-2
Vaccination

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. / Tanaka, Fumiaki; Yamaguchi, Hiroshi; Haraguchi, Naotsugu; Mashino, Kohjiro; Ohta, Mitsuhiko; Inoue, Hiroshi; Mori, Masaki.

In: International Journal of Oncology, Vol. 29, No. 5, 01.11.2006, p. 1263-1268.

Research output: Contribution to journalArticle

Tanaka, Fumiaki ; Yamaguchi, Hiroshi ; Haraguchi, Naotsugu ; Mashino, Kohjiro ; Ohta, Mitsuhiko ; Inoue, Hiroshi ; Mori, Masaki. / Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes. In: International Journal of Oncology. 2006 ; Vol. 29, No. 5. pp. 1263-1268.
@article{b4459e05393d42468fab49b73015f05f,
title = "Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes",
abstract = "Dendritic cells (DCs) are powerful antigenpresenting cells (APCs), that have so far been applied for cancer specific immunotherapy. Recent results suggest that matured DCs derived from human monocytes have a significant impact on the outcome of vaccination. The conventional generation of mature DCs from human monocytes in vitro has been reported to require 5 days for differentiation with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and 2 days for stimulation. We herein report a new strategy for the functional maturation of monocyte-derived DCs within only 2 days of in vitro culture and the induction of specific cytotoxic T lymphocytes (CTLs) to tumor rejection peptide. The monocytes were incubated for 1 day with GM-CSF and IL-4, followed by activation with a bacterial product, OK-432 and prostaglandin E 2 (PGE2) for another 1 day (rapid DC). Rapid DC expressed mature DC surface markers as well as chemokine receptor 7 and secreted Th1-type cytokines. The DCs genereated in this study mobilized Ca2+ in response to CCL21/6Ckine and SDF-1, but only marginally did so to Mip-1α. Moreover, when rapid DC were compared with mature conventional 7-day DCs, they were equally potent in inducing specific CTLs in vitro. These results indicate that the rapid DC is as effective as the monocyte-derived conventional DCs. The rapid DC would be a potentially useful new cancer-specific immunotherapy.",
author = "Fumiaki Tanaka and Hiroshi Yamaguchi and Naotsugu Haraguchi and Kohjiro Mashino and Mitsuhiko Ohta and Hiroshi Inoue and Masaki Mori",
year = "2006",
month = "11",
day = "1",
language = "English",
volume = "29",
pages = "1263--1268",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes

AU - Tanaka, Fumiaki

AU - Yamaguchi, Hiroshi

AU - Haraguchi, Naotsugu

AU - Mashino, Kohjiro

AU - Ohta, Mitsuhiko

AU - Inoue, Hiroshi

AU - Mori, Masaki

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Dendritic cells (DCs) are powerful antigenpresenting cells (APCs), that have so far been applied for cancer specific immunotherapy. Recent results suggest that matured DCs derived from human monocytes have a significant impact on the outcome of vaccination. The conventional generation of mature DCs from human monocytes in vitro has been reported to require 5 days for differentiation with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and 2 days for stimulation. We herein report a new strategy for the functional maturation of monocyte-derived DCs within only 2 days of in vitro culture and the induction of specific cytotoxic T lymphocytes (CTLs) to tumor rejection peptide. The monocytes were incubated for 1 day with GM-CSF and IL-4, followed by activation with a bacterial product, OK-432 and prostaglandin E 2 (PGE2) for another 1 day (rapid DC). Rapid DC expressed mature DC surface markers as well as chemokine receptor 7 and secreted Th1-type cytokines. The DCs genereated in this study mobilized Ca2+ in response to CCL21/6Ckine and SDF-1, but only marginally did so to Mip-1α. Moreover, when rapid DC were compared with mature conventional 7-day DCs, they were equally potent in inducing specific CTLs in vitro. These results indicate that the rapid DC is as effective as the monocyte-derived conventional DCs. The rapid DC would be a potentially useful new cancer-specific immunotherapy.

AB - Dendritic cells (DCs) are powerful antigenpresenting cells (APCs), that have so far been applied for cancer specific immunotherapy. Recent results suggest that matured DCs derived from human monocytes have a significant impact on the outcome of vaccination. The conventional generation of mature DCs from human monocytes in vitro has been reported to require 5 days for differentiation with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4 and 2 days for stimulation. We herein report a new strategy for the functional maturation of monocyte-derived DCs within only 2 days of in vitro culture and the induction of specific cytotoxic T lymphocytes (CTLs) to tumor rejection peptide. The monocytes were incubated for 1 day with GM-CSF and IL-4, followed by activation with a bacterial product, OK-432 and prostaglandin E 2 (PGE2) for another 1 day (rapid DC). Rapid DC expressed mature DC surface markers as well as chemokine receptor 7 and secreted Th1-type cytokines. The DCs genereated in this study mobilized Ca2+ in response to CCL21/6Ckine and SDF-1, but only marginally did so to Mip-1α. Moreover, when rapid DC were compared with mature conventional 7-day DCs, they were equally potent in inducing specific CTLs in vitro. These results indicate that the rapid DC is as effective as the monocyte-derived conventional DCs. The rapid DC would be a potentially useful new cancer-specific immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34250175330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250175330&partnerID=8YFLogxK

M3 - Article

C2 - 17016660

AN - SCOPUS:34250175330

VL - 29

SP - 1263

EP - 1268

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -